OBJECTIVES: To assess the follow-up level of the recommended guidelines for the treatment of Multiple Sclerosis (MS) developed by the Spanish Neurology Society (SEN) for the treatment of patients with relapsing remitting MS (RRMS) METHODS: Non-interventional, retrospective, and multicenter study that recruited patients with RRMS and clinical evolution of at least 5 years. Four hundred patients in 40 different centers are expected to be recruited in the ongoing study. The primary variable of the study (follow-up and monitoring of the SEN Guidelines for the management of MS patients) has been obtained by researchers’ ad-hoc questionnaire that includes activities and evaluation criteria taken into account when a therapeutic change should be considered. These changes should be made when there is a presence of an inadequate clinical response defined by one or more of the following circumstances: the same or higher number of relapses than during the previous year, ≥ 2 relapses/year, one relapse and one gadolinium enhancing lesion per year, and/or increase of 1 sustained point for the last six months without relapses (0.5 if EDSS ≥ 5.5 or 1.5 if EDSS = 0). RESULTS: The study is currently finalizing the inclusion of patients and the analyses are just being initiated. The FUTURA Study will evaluate the circumstances that determine treatment choice, therapeutic changes, and monitoring and control issues based on patient clinical history details, and if the decision to change treatment is made following the SEN guidelines for the treatment of such patients. CONCLUSIONS: The FUTURA Study will assess the follow-up and compliance of the Spanish Neurology Therapeutic MS Guidelines recommendations for the treatment of RRMS patients by Spanish neurologists.